Scisparc and clearmind medicine to conduct a study evaluating their combination treatment for obesity and metabolic syndrome

The treatment combines scisparc's palmitoylethanolamide (pea) , the active pharmaceutical ingredient of its proprietary cannamide ™ , and clearmind's meai, a novel proprietary psychedelic treatment for various addictions

SPRC Ratings Summary

SPRC Quant Ranking